Table of ContentsView AllTable of ContentsWhat Is MSA?SymptomsDiagnosisTreatmentCurrent Research

Table of ContentsView All

View All

Table of Contents

What Is MSA?

Symptoms

Diagnosis

Treatment

Current Research

Multiple system atrophy (MSA) is a disorder that causes multiple parts of the nervous system to degenerate. The older names for MSA include three syndromes: Shy-Drager syndrome,striatonigraldegeneration, andolivopontocerebellaratrophy.

MSA is a progressive disease affecting both the central nervous system (which controls how a person moves), and the ​autonomic nervous system, the part of your body that controls unconscious actions likeblood pressure, digestion, and breathing.

This article discusses the symptoms, diagnosis, and treatment options for multiple system atrophy.

DragonImages / iStock / Getty Images Plus

Older man with doctor

What Is Multiple System Atrophy?

MSA is usually diagnosed around 50 years of age and is seen in people of all ethnic backgrounds. Once symptoms begin, the disease tends to progress quickly over five to 10 years.The average life expectancy is seven to nine years.

Symptoms of Multiple System Atrophy

MSA symptoms stem from the loss of nerve cells in the nervous system including the basal ganglia and cerebellum. What causes this loss of nerve cells is still unknown. Many people with MSA first noticesymptoms such as:

As symptoms progress, they typically fall under one of two groups:

Other symptoms associated with MSA include:

How Is MSA Diagnosed?

It can be very difficult to distinguish MSA from Parkinson’s disease. One way to differentiate between the two is to look at how quickly the disease progresses.MSA tends to progress faster than Parkinson’s does. Many people with MSA will need an assistive device, like a wheelchair or cane, within several years of being diagnosed.

Another way to differentiate between the two is to treat for Parkinson’s. MSA does not respond well to levodopa, the medication that is used to treat Parkinson’s.Unfortunately, an autopsy is the only way to definitively diagnose MSA. Specialized testing, such as aPET scan(positron emission tomography), can rule out other types of rare neurological disorders.

Treatment for Multiple System Atrophy

Currently, there is no cure for MSA, nor are there any treatments specifically designed to reverse or stop disease progression. Some aspects of the disorder are debilitating and difficult to treat. Treatments may include:

What the Research Says

Little is known about the mechanisms at work in multiple system atrophy. Researchers are currently trying to figure out why the proteinalpha-synucleinbuilds up in theglialcells (cells that protect neurons in the nervous system) of people with MSA and the neuronal (nerve) cells of people with Parkinson’s disease.

A clinical trial tried using the drug rifampicin to slow down disease progression, but the treatment was ineffective.Data from this study is now being used in other MSA studies.

Summary

Multiple system atrophy is a progressive disease that can affect physical movement, blood pressure, digestion, breathing, and swallowing. The cause of MSA is unknown and diagnosis is often delayed because the condition has similar symptoms as other neurodegenerative diseases. There currently is no cure so treatment options focus on reducing symptoms as best as possible.

4 SourcesVerywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.National Institute of Neurological Disorders and Stroke.Multiple system atrophy.Goh YY, Saunders E, Pavey S, et al.Multiple system atrophy. Pract Neurol. 2023 Jun;23(3):208-221. doi: 10.1136/pn-2020-002797Foubert-Samier A, Pavy-Le Traon A, Guillet F, et al.Disease progression and prognostic factors in multiple system atrophy: A prospective cohort study. Neurobiology of Disease. 2020;139:104813. doi: 10.1016/j.nbd.2020.104813Low PA, Robertson D, Gilman S, Kaufmann H, et al.Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014 Mar;13(3):268-75. doi: 10.1016/S1474-4422(13)70301-6Additional ReadingNational Institute of Neurological Disorders and Stroke. Multiple System Atrophy Fact Sheet. November 2014.

4 Sources

Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.National Institute of Neurological Disorders and Stroke.Multiple system atrophy.Goh YY, Saunders E, Pavey S, et al.Multiple system atrophy. Pract Neurol. 2023 Jun;23(3):208-221. doi: 10.1136/pn-2020-002797Foubert-Samier A, Pavy-Le Traon A, Guillet F, et al.Disease progression and prognostic factors in multiple system atrophy: A prospective cohort study. Neurobiology of Disease. 2020;139:104813. doi: 10.1016/j.nbd.2020.104813Low PA, Robertson D, Gilman S, Kaufmann H, et al.Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014 Mar;13(3):268-75. doi: 10.1016/S1474-4422(13)70301-6Additional ReadingNational Institute of Neurological Disorders and Stroke. Multiple System Atrophy Fact Sheet. November 2014.

Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.

National Institute of Neurological Disorders and Stroke.Multiple system atrophy.Goh YY, Saunders E, Pavey S, et al.Multiple system atrophy. Pract Neurol. 2023 Jun;23(3):208-221. doi: 10.1136/pn-2020-002797Foubert-Samier A, Pavy-Le Traon A, Guillet F, et al.Disease progression and prognostic factors in multiple system atrophy: A prospective cohort study. Neurobiology of Disease. 2020;139:104813. doi: 10.1016/j.nbd.2020.104813Low PA, Robertson D, Gilman S, Kaufmann H, et al.Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014 Mar;13(3):268-75. doi: 10.1016/S1474-4422(13)70301-6

National Institute of Neurological Disorders and Stroke.Multiple system atrophy.

Goh YY, Saunders E, Pavey S, et al.Multiple system atrophy. Pract Neurol. 2023 Jun;23(3):208-221. doi: 10.1136/pn-2020-002797

Foubert-Samier A, Pavy-Le Traon A, Guillet F, et al.Disease progression and prognostic factors in multiple system atrophy: A prospective cohort study. Neurobiology of Disease. 2020;139:104813. doi: 10.1016/j.nbd.2020.104813

Low PA, Robertson D, Gilman S, Kaufmann H, et al.Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014 Mar;13(3):268-75. doi: 10.1016/S1474-4422(13)70301-6

National Institute of Neurological Disorders and Stroke. Multiple System Atrophy Fact Sheet. November 2014.

Meet Our Medical Expert Board

Share Feedback

Was this page helpful?Thanks for your feedback!What is your feedback?OtherHelpfulReport an ErrorSubmit

Was this page helpful?

Thanks for your feedback!

What is your feedback?OtherHelpfulReport an ErrorSubmit

What is your feedback?